Drug intelligence / Profile preview

obtustatin

Development stage
Preclinical
Modality
Peptides
Administration
Intraperitoneal, Intratumoral, Intravenous
01

Overview

Obtustatin is a highly potent, selective, non-RGD-containing short disintegrin peptide originally isolated from the venom of the viper *Vipera lebetina obtusa*. Composed of 41 amino acids, it is the shortest known disintegrin and features a KTS (Lys-Thr-Ser) active site motif instead of the classical RGD sequence. Obtustatin specifically and potently inhibits the binding of integrin α1β1 (CD49a/CD29) to collagen IV with an IC50 of approximately 0.8 to 2 nM, without affecting other closely related integrins such as α2β1 or αIIbβ3. By blocking integrin α1β1 signaling, obtustatin inhibits endothelial cell proliferation, induces apoptosis, and suppresses angiogenesis. It has demonstrated significant anti-angiogenic and antitumor efficacy in preclinical animal models of melanoma, Lewis lung carcinoma, and sarcoma, and is widely utilized as a research tool to study integrin biology, angiogenesis, and inflammatory processes.

Other names
disintegrin obtustatinKTS-disintegrin
02

Targets

ITGA1 (Integrin Subunit Alpha 1)ITGA2/ITGB1 (Integrin alpha-2/beta-1 receptor)ITGB1 (Integrin beta-1)

Beyond the preview

Go deeper on obtustatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on obtustatin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call